Cargando…
CD95L and Anti-Tumor Immune Response: Current Understanding and New Evidence
The ability of FasL/CD95L to induce apoptosis in various Fas/CD95-expressing cells has been described in the context of hematopoiesis or thymic elimination of self-reactive T cells and resolution of an acute immune response under physiological conditions. At the same time, non-apoptotic CD95 activat...
Autores principales: | Richards, David M, Merz, Christian, Gieffers, Christian, Krendyukov, Andriy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7981134/ https://www.ncbi.nlm.nih.gov/pubmed/33758545 http://dx.doi.org/10.2147/CMAR.S297499 |
Ejemplares similares
-
Asunercept as an innovative therapeutic approach for recurrent glioblastoma and other malignancies
por: Krendyukov, Andriy, et al.
Publicado: (2019) -
Neutralization of the CD95 ligand by APG101 inhibits invasion of glioma cells in vitro
por: Merz, Christian, et al.
Publicado: (2015) -
A Single-Chain-Based Hexavalent CD27 Agonist Enhances T Cell Activation and Induces Anti-Tumor Immunity
por: Thiemann, Meinolf, et al.
Publicado: (2018) -
Concepts for agonistic targeting of CD40 in immuno-oncology
por: Richards, David M., et al.
Publicado: (2019) -
The CD40 agonist HERA-CD40L results in enhanced activation of antigen presenting cells, promoting an anti-tumor effect alone and in combination with radiotherapy
por: Frankish, Jamie, et al.
Publicado: (2023)